Redeye: Camurus Q2 2025 - Deal with Eli Lilly
Refinitiv閱讀少於1分鐘
Redeye comments on Camurus' Q2 report 2025, which was in line with our estimates on a constant currency basis. The main events that increase our base case are the deal with Eli Lilly and the positive phase II results of CAM2029 in polycystic liver disease.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
登入或建立一個永久免費帳戶來閱讀此新聞